SLCO1B3 and prostate carcinoma: OATP1B3 is expressed de novo in prostate cancer as compared to surrounding normal prostate tissue and is expressed more frequently and to a greater degree in prostate cancer metastases, and therefore potentially plays a role in mediating intra-tumoral androgen concentration4–8.